Clinical trials are beginning for the first drug developed using machine learning, in a partnership between Sumitomo Dainippon Pharma Co and Exscientia.
The new drug is intended to deliver much faster results in the treatment of obsessive-compulsive disorders (OCD).
Artificial intelligence and machine learning have been appearing across various fields in recent years. In fact, both systems are already actively used in the healthcare sector.
One of the most significant developments to date is a drug developed entirely through machine learning.
The Japanese pharmaceutical company Sumitomo Dainippon Pharma Co, in collaboration with the AI project Exscientia, prepared the first drug developed through machine learning for clinical trials within just 12 months.
What is machine learning?
Machine learning is a scientific discipline focused on the design and development of algorithms that enable computers to learn from data types such as sensor data or databases.
In fact, the newly developed drug aims to provide significantly faster results in the treatment of OCD.
It is believed that this psychological disorder could be treated more effectively with the impact of a machine learning-developed drug.
Another major advantage of this system is the reduced cost of bringing a new drug to market.
Machine learning offers a crucial benefit here as well, as it can determine a drug’s usability in a shorter time and at lower cost.